linjc16/ctgov huggingface dataset:
The Treatment of the Median Nerve for the Elimination of the Symptoms Associated With the Carpal Tunnel Syndrome

Study Overview
=================
Brief Summary
-----------------
In carpal tunnel syndrome,trigger points are often found in the biceps muscle,in the aponeurosis of the biceps and in the pronator teres muscle. We hypothesise that by eliminating these trigger points,using ischemic compressions, may diminish the symptoms.

Detailed Description
-----------------
Using one thumb on the other,the pressure is applied 10 seconds on each TrPs.The treatment is done on each visit for a total of 15(without Charge).

Official Title
-----------------
Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study

Conditions
-----------------
Compression Neuropathy, Carpal Tunnel

Intervention / Treatment
-----------------
* Procedure: Ischemic Compression (thumb Pressure)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 20 and 60 years old, Numbness in the hand affecting the thumb, the index finger, the middle finger and half the ring finger, To have suffered from discomfort on a daily basis for at least three months and to agree to a course of 15 chiropractic treatments at no cost. Exclusion Criteria: History of upper limb or neck surgery, Pregnancy and systemic pathologies possibly related to CTS, such as hypothyroidism, diabetes and rheumatoid arthritis.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: one<br> | Procedure: Ischemic Compression (thumb Pressure)<br>* Pressure, one thumb on the other, applied on the trigger points<br>* Other names: Pressure point therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levine DW Questionnaire (J.Bone Joint Surg Am 1993;75:1585-92)on carpal tunnel syndrome |  | after 15treatments,30 days after,6 months later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A numerical scale,filled by the patient,where they give their perceived improvement from 0% to 100%. |  | After 15 treatments, 30 days later and 6 months later. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ischemic compression;carpal tunnel syndrome
Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
This study evaluates the safety and efficacy of once-daily bimatoprost 0.03% and 0.01% ophthalmic solutions compared with once-daily administered bimatoprost vehicle ophthalmic solution for 2 weeks in ethnically Japanese patients with open-angle glaucoma or ocular hypertension

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Bimatoprost 0.01% Ophthalmic Solution
* Drug: Bimatoprost 0.03% Ophthalmic Solution
* Drug: Bimatoprost Vehicle Ophthalmic Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ethnically Japanese patients with glaucoma or ocular hypertension in each eye who require IOP-lowering therapy in both eyes Exclusion Criteria: Uncontrolled systemic disease Use of bimatoprost or an ocular prostaglandin (eg, latanoprost, travoprost) within 6 weeks prior to baseline (Day 0)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Bimatoprost 0.01% Ophthalmic Solution | Drug: Bimatoprost 0.01% Ophthalmic Solution<br>* Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00<br>|
| Experimental: 2<br>Bimatoprost 0.03% Ophthalmic Solution | Drug: Bimatoprost 0.03% Ophthalmic Solution<br>* Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00<br>* Other names: LUMIGAN®;|
| Placebo Comparator: 3<br>Bimatoprost Vehicle Ophthalmic Solution | Drug: Bimatoprost Vehicle Ophthalmic Solution<br>* Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular pressure (IOP) |  | Day 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP |  | Days 2 and 7 |
Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
Investigators aimed to investigate the association between over active bladder and coronary artery disease as demonstrated on coronary angiography.

Detailed Description
-----------------
The close relationship has been demonstrated between pelvic ischemia and overactive bladder (OAB) in a study involving elderly patients. In this study, it has been found that pelvic ischemia has triggered OAB and it has been related with cardiac ischemia. The aim of this study was to delineate the correlation between OAB and the degree of coronary artery stenosis as demonstrated on coronary angiography.

Official Title
-----------------
Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease

Conditions
-----------------
Overactive Bladder Syndrome, Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients, whom were diagnosed to undergo coronary angiography in a center of cardiology Exclusion Criteria: a maximum flow rate of 15 ml. per second or less, residual volume of 100 cc or more, diabetes mellitus, neurologic disease, prostate or bladder cancer, renal failure, urinary tract infection, nephrolithiasis or pelvic surgery, patients with a history of percutaneous coronary intervention or coronary artery bypass grafting

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Patients with a OAB-V8 score ≥8 | |
| Group 2<br>Patients with a OAB-V8 score <8 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Over active bladder V8 questionnaire score |  | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
overactive bladder, coronary artery disease, gensini score
A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors

Study Overview
=================
Brief Summary
-----------------
Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were selected from the first chemotherapy cycle using PEG-rhG-CSF (can be any chemotherapy cycle of the patient), and each subsequent chemotherapy cycle was recorded. The use of PEG-rhG-CSF and related patient outcomes until the end of chemotherapy. Analyze the clinical practice of using PEG-rhG-CSF in the real world.

Official Title
-----------------
A Prospective, Multicenter, Non-interventional Registry Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Malignant Solid Tumors in Sichuan

Conditions
-----------------
Neutropenia

Intervention / Treatment
-----------------
* Drug: Pegfilgrastim（PEG-rhG-CSF）


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old; Diagnosed as a malignant solid tumor by histology and cytology, requiring chemotherapy patients; The first use of PEG-rhG-CSF during the chemotherapy cycle (not limited to the first chemotherapy cycle, can be any chemotherapy cycle of the patient); Subjects volunteered to participate in this clinical trial and signed informed consent. Exclusion Criteria: PEG-rhG-CSF was used in the current chemotherapy cycle; Have received hematopoietic stem cell transplantation or bone marrow transplantation; Other drug clinical trials are currently underway.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dosage of PEG-rhG-CSF in chemotherapy |  | 1 YEAR | 
| Administration time of PEG-rhG-CSF in chemotherapy |  | 1 YEAR | 
| dosing frequency of PEG-rhG-CSF in chemotherapy |  | 1 YEAR |
Mechanism of Effectiveness of Neurosurgery Treatments for Durable Pain

Study Overview
=================
Brief Summary
-----------------
The participants in the study are patients who undergo surgery to damaged nerve transmission and processing system in the nervous system as part of the routine clinical treatment that will not be affected by the proposed study. Patients who are candidates for procedures are referred from all over the country and undergo a multidisciplinary evaluation in the framework of the Palliative Pain Management Clinic, which operates exclusively in Israel at the Sourasky Medical Center in Tel Aviv.

Detailed Description
-----------------
The participants in the study are patients who undergo surgery to damaged nerve transmission and processing system in the nervous system as part of the routine clinical treatment that will not be affected by the proposed study. Patients who are candidates for procedures are referred from all over the country and undergo a multidisciplinary evaluation in the framework of the Palliative Pain Management Clinic, which operates exclusively in Israel at the Sourasky Medical Center in Tel Aviv. During the preoperative evaluation, patients will be given an explanation about the possibility of participating in the study. Patients who agree to participate will sign an informed consent form.

Official Title
-----------------
Mechanism of Effectiveness of Neurosurgery Treatments for Durable Pain

Conditions
-----------------
Oncology Problem

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing neurosurgical surgery for resistant pain Ability to sign informed consent form for participation in the study A functional level is sufficient for cooperation and the performance of various tasks before and after surgery, including performing MRI's, answering pain questioners, and neuropsychological evaluations. Exclusion Criteria: Refusal to participate Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
resistant pain
Genetic Study of Familial Epilepsy

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Determine the chromosomal regions that contain genes that raise the risk of epilepsy in families by performing genetic linkage analysis of idiopathic/cryptogenic epilepsy.

Detailed Description
-----------------
PROTOCOL OUTLINE: Family histories are obtained, then the patients undergo an interview, a neurological examination, and EEG. Blood specimens are also collected. Linkage analysis is performed on specimens and analysis of shared marker alleles are used to identify genomic regions likely or unlikely to contain the epilepsy genes. Genotypes in family members are determined at microsatellite markers throughout the genome. Markers tested include chromosomes linked to human epilepsy syndromes (6p, 8p, 8q, 20q, 21q) and chromosome 3 (similar to mouse epilepsy genes). Linkage to markers on chromosome 10q are also tested. Patients do not receive the results of the testing and the results do not influence the type and duration of any treatment.

Conditions
-----------------
Epilepsy

Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Male or female members of families with at least 1 close relative pair (sibling, half sibling, avuncular, grandparent-grandchild, or first cousin) affected with idiopathic/cryptogenic epilepsy that developed before age 25

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
epilepsy, rare disease, neurologic and psychiatric disorders, seizures
Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System

Study Overview
=================
Brief Summary
-----------------
The goal of this research is to test a distal scanning capsule and a compact redesigned version of the OFDI imaging system in healthy and BE subjects to assess ease of use, safety and feasibility in preparation for its use in a multicenter clinical trial.

Detailed Description
-----------------
Ten healthy volunteer subjects and ten volunteers with a previous diagnosis of Barrett's Esophagus (BE) will be enrolled in the study. The capsule is attached to a string-like tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus using peristalsis. Images of the esophagus will be acquired in real time to be analyzed later.

Official Title
-----------------
Pilot Study for TCE (Tethered Capsule Endomicroscopy) Imaging of the Esophagus Using an OFDI (Optical Frequency Domain Imaging) Capsule With a Compact Imaging System

Conditions
-----------------
Barrett's Esophagus

Intervention / Treatment
-----------------
* Device: Experimental OFDI Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A previous diagnosis of BE (not an inclusion criteria for healthy volunteers) Subjects must be over the age of 18 but less than 70 year of age. Subjects must be able to give informed consent Subjects must have no solid food for 4 hours prior to the procedure, and only clear liquids for 2 hours prior to the procedure. Exclusion Criteria: Subjects over 70 years of age Subjects with the inability to swallow pills and capsules. Subjects with a strong gag reflex Esophageal fistula and/or esophageal strictures with a stricture diameter that is smaller than the diameter of the capsule. Pregnancy. If the subject is unsure, she will be asked to take a pregnancy test.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: OFDI Imaging<br>Experimental OFDI Imaging | Device: Experimental OFDI Imaging<br>* Imaging of the esophagus with a compact OFDI system and distal scanning catheter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of quality and performance of Compact Imaging System (CIS) | Images obtained from the CIS will be assessed for quality and compared to images acquired from the previous imaging system | 5-7 Minutes of imaging | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Device, OFDI, Tethered Capsule Endomicroscopy
Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases

Study Overview
=================
Brief Summary
-----------------
This study aims to determine whether a test, called the PET scan, may be useful in determining if there are additional locations of cancer not otherwise detectable by other tests. The PET scan is a nuclear medicine imaging study that measures how much radioactive sugar is used by your tumor. The study will compare pictures of the cancer from the PET scan to other x-ray exams, such as a CT scan, as well as to what your doctors find at the time of surgery. If the study results show that the PET scan gives us a good idea of what is happening to the tumor, then it may be useful in deciding which patients with colorectal metastases to the liver should be operated on and what operation should be performed. Additionally, by comparing the results of PET scans with the other studies that will be performed as part of your care, we will try to determine which test best tells us which patient is most likely to benefit from surgery.

Official Title
-----------------
Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases

Conditions
-----------------
Colorectal Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: initial diagnosis of colorectal carcinoma confirmed by the Pathology Department of Memorial Hospital or by diagnostic barium enema if the primary tumor is still in place. a candidate for liver resection for metastatic colorectal cancer as defined by members of the Department of Surgery of Memorial Hospital. Patients with metastatic colorectal cancer isolated to the colon, rectum, or liver are eligible. In addition, patients with limited, resectable pulmonary metastases are eligible. Exclusion Criteria: Patients must not be pregnant; females of child bearing age must use an adequate form of contraception.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors. |  | conclusion of the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases. |  | conclusion of the study |
Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding

Study Overview
=================
Brief Summary
-----------------
Whether beta-blockers or banding is the best therapy for primary prophylaxis of variceal bleeding is subject to debate. A randomized comparison between the two treatments was performed in candidates for liver transplantation. Patients with Child B and C cirrhosis with high risk varices and no previous variceal bleeding are randomized to propranolol or variceal bleeding. Primary end point is variceal bleeding

Official Title
-----------------
Randomized Study Comparing Ligation With Propranolol for Primary Prophylaxis of Variceal Bleeding in Candidates for Liver Transplantation

Conditions
-----------------
Liver Cirrhosis, Esophageal Varices

Intervention / Treatment
-----------------
* Procedure: endoscopic variceal banding
* Drug: propranolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: liver cirrhosis child pugh>=B7 studied for transplantation age between 18 an 65 ys no previous bleeding from varices signed informed consent Exclusion Criteria: esophageal varices less than F2 blue gastric varices previous variceal surgical or radiological or endoscopical treatment hepatocarcinoma portal vein thrombosis severe heart, respiratory or renal failure contraindications to betablockers treatment with nitrates, calcium antagonist or anti-arhythmic drugs that can not be suspended Pregnancy neoplasias non cooperation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: endoscopic variceal banding|nan|
|Drug: propranolol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| variceal bleeding |  |  |